IP Library Granted Patent US 9,765,154
Granted Patent B2
US 9,765,154 · App. 14/708,677 · Granted Sep 19, 2017

Phosphohistidine analogs

Inventors: Tom W. Muir (Princeton, NJ); Jung-Min Kee (Plainsboro, NJ)
Assignee: THE ROCKEFELLER UNIVERSITY
C07K16/44A61K31/675A61K47/4833A61K47/48061C07F9/65182C07F9/65186C07D249/04C07F9/4015C07K2317/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,765,154
App. No.
14/708,677
Granted
Sep 19, 2017
Kind
B2
Abstract

The present invention relates to the phosphohistidine analogs of the present invention which of the formula and the hapten containing the residue of same. It also relates to the hapten conjugated to a carrier molecule and the isolated antibodies raised against the immunogens, said antibodies recognizing polypeptide containing a phosphorylated histidine or the phosphotriazole residue but it does not recognize an amino acid or polypeptide that is not phosphorylated or a polypeptide which is phosphorylated on amino acids other than histidine but not on histidine.

Claims (33)

1. An isolated antibody that specifically recognizes a phosphohistidine or a phosphopolypeptide having at least one histidine thereon which is phosphorylated, said antibody does not recognize a non-phosphorylated histidine, other phosphoamino acids and polypeptide which does not have a phosphorylated histidine.

2. The isolated antibody according to claim 1 wherein the antibody is raised against a hapten having the formula:

wherein X 1 and Y 1 are independently a bond,

or a salt thereof wherein

Z is CH, N or SiR 11 ;

R 11 is an alkyl group or H,

E and G are independently a chemical bond or a linker group selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenyl alkyl, heterocyclic, heterocyclic alkyl, (O—CH 2 — CH 2 )n, and (CH 2 )q wherein one of the CH 2 groups is replaced by O,

n is 1-100;

q is 1-6;

one of R and R 1 is H and the other is

and R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are independently hydrogen, alkyl, alkenyl, cycloalkyl, aryl, cycloalkylalkyl, aryl alkyl, heterocyclic, or heterocyclicalkyl.

3. The isolated antibody according to claim 2 wherein E and G are both a chemical bond.

4. The isolated antibody according to claim 2 wherein X 1 is

and Y 1 is

or Y 1 is

and X 1 is

5. The isolated antibody according to claim 3 wherein X 1 is

and Y 1 is

or Y 1 is

and X 1 is

6. The isolated antibody of claim 1 wherein the antibody is a monoclonal or polyclonal antibody.

7. The isolated antibody of claim 1 which is a humanized form thereof, a chimeric form thereof or a fragment thereof.

8. The isolated antibody according to claim 2 wherein the hapten has the formula

wherein X 2 is linked to the NH group and Y 2 is linked to the carbonyl group of the structure which is shown within the parenthesis, and where one of R 1 and R is

or anion thereof and the other is 1-1 and Y 2 is OH or an amino acid residue of 1-15 amino acids and X 2 is H, an amino acid residue of 1-15 amino acids wherein the amino acids are selected from the group consisting of Gly, Ala, Val, Leu, Ile, Asp, Glu, Asn, Gln, Lys, His, Pro, Phe, Trp, Tyr, Ser, Thr, Met, Cys and Arg, or

wherein X 1 is a bond or H and Y 1 is a bond or OH and wherein the sum of the amino acid residues in X 2 and Y 2 ranges from 1 to about 200.

9. The isolated antibody of claim 2 wherein the hapten is comprised of a phosphoryltriazole fragment having the structure

10. The isolated antibody according to claim 2 wherein the hapten has an amino acid sequence selected from SEQ. ID NO. 1-8, 12, 13, 18, and 23.

11. The isolated antibody according to claim 10 wherein the hapten has the amino acid sequence of SEQ ID NO. 12.

12. An antibody fragment of the isolated antibody of claim 1 , wherein the antibody fragment is selected from the group consisting of Fab, Fab′, F(ab′) 2 , and Fe fragments; diabodies; linear antibodies; and single-chain antibody molecules.

13. A composition comprising the isolated antibody of claim 1 .

14. A composition comprising the isolated antibody of claim 6 .

15. A composition comprising the isolated antibody of claim 7 .

Assignments (1)
CONFIRMATORY LICENSE Recorded Dec 18, 2015
From: ROCKEFELLER UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 037334/0927 →
Continuity (3)
Division 13825699
Provisional Application 61386424 · Sep 24, 2010
Related Publication 20150344589A1 · Dec 3, 2015